Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor TS ID 12061Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC